Tasigna (nilotinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor. In Philadelphia chromosome-positive chronic myeloid leukemia, the BCR-ABL protein activates a number of cell cycle-controlling proteins and enzymes, speeding up cell division. The binding of Tasigna to the BCR-ABL protein blocks the signal that leads to the production of leukemic cells.
Novartis will continue to look to Tasigna to make up for Gleevec's (imatinib; Novartis) downturn caused by the entry of generic imatinib into the chronic myeloid leukemia (CML) market. The second-generation tyrosine kinase inhibitor (TKI) has displayed cytogenetic and molecular response rates superior to those of Gleevec, but is likely to see its use remain primarily in the second-line setting alongside direct competitor Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka).
Key Topics Covered:
List of Figures
Figure 1: Tasigna for CML - SWOT analysis
Figure 2: Drug assessment summary of Tasigna for CML
Figure 3: Drug assessment summary of Tasigna for CML
List of Tables
Table 1: Tasigna drug profile
Table 2: Tasigna pivotal trial data in CML
Table 3: Tasigna late-phase trial data in CML
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/trj9x7/tasigna?w=4